GlassScriptPhysician profile
Shahriar Sedghi
NPI 1689659260
$6,602.90
in general payments reported to CMS, 2019-2025
48 companies · $876 in 2025
The $876 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $546 · 2021: $1,407 · 2022: $1,056 · 2023: $1,156 · 2024: $902 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,916 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,915.77 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,140.73 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Janssen Biotech, INC. | $494.76 | 2019-2025 | Stelara, Tremfya |
| Medtronic, INC. | $453.15 | 2023-2025 | Interstim |
| Gilead Sciences, INC. | $404.57 | 2019-2025 | |
| Celgene Corporation | $379.76 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $365.08 | 2019-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $351.01 | 2020-2024 | Dificid |
| Boston Scientific Corporation | $226.01 | 2019-2023 | |
| Aroa Biosurgery Incorporated | $215.05 | 2022-2024 | |
| Pfizer INC. | $214.27 | 2019-2023 | |
| Intercept Pharmaceuticals, INC. | $213.17 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $186.39 | 2021-2025 | Entyvio, Gattex |
| Evoke Pharma, INC. | $174.21 | 2020-2023 | Gimoti |
| Novo Nordisk INC | $109.80 | 2025 | |
| Qol Medical, LLC | $80.21 | 2019-2023 | Sucraid |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $68.78 | 2019-2021 | |
| Lilly USA, LLC | $60.56 | 2023-2025 | Omvoh |
| Amgen INC. | $42.70 | 2021 | |
| Ferring Pharmaceuticals INC. | $39.05 | 2021-2023 | Clenpiq |
| Celltrion USA INC. | $38.96 | 2025 | Vegzelma |
| Allergan, INC. | $33.31 | 2020 | |
| Axonics, INC. | $29.87 | 2021 | |
| Ucb, INC. | $27.40 | 2019 | |
| Nestle Healthcare Nutrition INC. | $24.94 | 2022 | |
| Genzyme Corporation | $24.92 | 2024 | |
| Mauna Kea Technologies, INC. | $23.94 | 2025 | |
| Aimmune Therapeutics, INC. | $20.70 | 2024 | |
| Vivus LLC | $20.59 | 2021 | |
| Redhill Biopharma INC. | $19.06 | 2020 | |
| Daiichi Sankyo INC. | $17.73 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.04 | 2025 | Iqirvo |
| Romark Laboratories, Lc | $16.42 | 2019 | |
| Mylan Institutional INC. | $15.99 | 2023 | Hulio |
| Ardelyx, INC. | $14.71 | 2025 | Ibsrela |
| Braintree Laboratories, INC. | $14.30 | 2021 | |
| Csl Behring | $12.76 | 2021 | |
| Intra-Sana Laboratories | $11.00 | 2021 |
11 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$8,547.66 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahriar Sedghi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.